CPT® Code 90287

1. Indications

The equine botulinum antitoxin is indicated for use in patients who have been exposed to botulinum toxins, which can lead to botulism, a potentially life-threatening condition. The following conditions warrant the administration of this antitoxin:

• Botulism Exposure Patients who have been diagnosed with or are suspected of having botulism due to exposure to botulinum toxins.
• Preventive Treatment Individuals at high risk of botulism, such as those in outbreak situations or those who have ingested contaminated food products.

2. Procedure

The administration of equine botulinum antitoxin involves several key procedural steps to ensure effective delivery and patient safety. Each step is critical in the overall process of providing this immunizing agent.

• Step 1: Patient Assessment Prior to administration, a thorough assessment of the patient is conducted to confirm the diagnosis of botulism or potential exposure to botulinum toxins. This may include reviewing the patient's medical history, symptoms, and any recent food intake that could indicate exposure.
• Step 2: Preparation of Antitoxin The equine botulinum antitoxin is prepared according to the manufacturer's guidelines. This includes checking the product for any signs of contamination or expiration and ensuring that it is stored at the appropriate temperature prior to use.
• Step 3: Administration The antitoxin is administered via the appropriate route, which may include intravenous, intramuscular, or subcutaneous injection, depending on the clinical scenario and physician's discretion. Care is taken to follow aseptic techniques to minimize the risk of infection.
• Step 4: Monitoring After administration, the patient is monitored for any adverse reactions or side effects. This includes observing for allergic reactions, which can occur with equine-derived products, and ensuring that the patient is stable.

3. Post-Procedure

Following the administration of the equine botulinum antitoxin, patients should be monitored for a period to assess for any immediate reactions. It is essential to provide supportive care as needed, which may include managing symptoms of botulism and ensuring the patient remains hydrated. Patients may require follow-up evaluations to monitor their recovery and to assess the effectiveness of the antitoxin. Documentation of the administration, including the dosage, route, and any observed reactions, is crucial for compliance and future reference.